Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 6/2010

01.12.2010 | Review Paper

Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship

verfasst von: Pria Anand, Sandra A. Springer, Michael M. Copenhaver, Frederick L. Altice

Erschienen in: AIDS and Behavior | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Cognitive impairment among populations at risk for HIV poses a significant barrier to managing risk behaviors. The impact of HIV and several cofactors, including substance abuse and mental illness, on cognitive function is discussed in the context of HIV risk behaviors, medication adherence, and risk-reduction interventions. Literature suggests that cognitive impairment is intertwined in a close, reciprocal relationship with both risk behaviors and medication adherence. Not only do increased risk behaviors and suboptimal adherence exacerbate cognitive impairment, but cognitive impairment also reduces the effectiveness of interventions aimed at optimizing medication adherence and reducing risk. In order to be effective, risk-reduction interventions must therefore take into account the impact of cognitive impairment on learning and behavior.
Literatur
1.
World Health Organization. Report on the global AIDS epidemic. Geneva, Switzerland; 2008.
2.
Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. Curr Drug Abuse Rev. 2009;2(2):143–56.CrossRefPubMed
3.
Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152–68.CrossRefPubMed
4.
Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009;19(2):169–85.CrossRefPubMed
5.
Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32(5):389–405.CrossRefPubMed
6.
Gray F, Adle-Biassette H, Chretien F, et al. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol. 2001;20(4):146–55.PubMed
7.
8.
Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc. 2002;8(3):410–24.CrossRefPubMed
9.
Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66(9):1447–50.CrossRefPubMed
10.
Applebaum AJ, Otto MW, Richardson MA, Safren SA. Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsychol. 2009:1–11.
11.
Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res. 2005;8(1–2):119–34.CrossRefPubMed
12.
Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1999;12(3):184–92.PubMed
13.
Mayer K, Pizer H. HIV prevention: a comprehensive approach. London: Academic Press; 2008.
14.
Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.PubMed
15.
Rapeli P, Kivisaari R, Autti T, et al. Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry. 2006;6:9.
16.
Verdejo-Garcia A, Lopez-Torrecillas F, Gimenez CO, Perez-Garcia M. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol Rev. 2004;14(1):1–41.CrossRefPubMed
17.
Di Franco MJ, Marlink R, Hunter DJ, et al. Association of immune activation with intravenous heroin use and methadone treatment in HIV-1 seropositive and seronegative subjects. J Acquir Immune Defic Syndr. 1993;6(12):1297–300.PubMed
18.
Margolin A, Avants SK, Warburton LA, Hawkins KA. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDS. 2002;16(6):255–67.CrossRefPubMed
19.
Copenhaver M, Avants SK, Warburton LA, Margolin A. Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoactive Drugs. 2003;35(2):209–18.PubMed
20.
Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol. 1998;4(6):619–26.CrossRefPubMed
21.
Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am. 2007;21(1):149–79.CrossRefPubMed
22.
McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci. 1998;18(20):8417–22.PubMed
23.
Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry. 2005;162(8):1461–72.CrossRefPubMed
24.
Simon SL, Domier C, Carnell J, et al. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000;9(3):222–31.CrossRefPubMed
25.
Coffey SF, Gudleski GD, Saladin ME, Brady KT. Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals. Exp Clin Psychopharmacol. 2003;11(1):18–25.CrossRefPubMed
26.
Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15(3):317–25.PubMed
27.
Simon SL, Domier CP, Sim T, et al. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis. 2002;21(1):61–74.CrossRefPubMed
28.
Wilson J, Kalasinsky K, Levey A, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2(6):699–703.CrossRefPubMed
29.
Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry. 1981;44(8):728–30.CrossRefPubMed
30.
Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson’s disease. Neurotoxicology. 2006;27(6):1003–6.CrossRefPubMed
31.
Moszczynska A, Fitzmaurice P, Ang L, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain. 2004;127(2):363–70.CrossRefPubMed
32.
Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95(5):687–95.CrossRefPubMed
33.
Brandt J, Butters N, Ryan C, Bayog R. Cognitive loss and recovery in long-term alcohol abusers. Arch Gen Psychiatry. 1983;40(4):435–42.PubMed
34.
Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry. 2004;161(2):249–54.CrossRefPubMed
35.
Cook CC, Hallwood PM, Thomson AD. B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Alcohol Alcohol. 1998;33(4):317–36.PubMed
36.
Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend. 2005;78(3):283–8.CrossRefPubMed
37.
Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5.CrossRefPubMed
38.
Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492–7.CrossRefPubMed
39.
Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64(8):1343–7.PubMed
40.
Cournos F, McKinnon K, Wainberg M. What can mental health interventions contribute to the global struggle against HIV/AIDS? World Psychiatry. 2005;4(3):135–41.PubMed
41.
Jaffe MP, O’Neill J, Vandergoot D, Gordon WA, Small B. The unveiling of traumatic brain injury in an HIV/AIDS population. Brain Inj. 2000;14(1):35–44.CrossRefPubMed
42.
Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev. 2005;25(4):433–57.CrossRefPubMed
43.
Weinhardt LS, Carey MP, Carey KB, Maisto SA, Gordon CM. The relation of alcohol use to HIV-risk sexual behavior among adults with a severe and persistent mental illness. J Consult Clin Psychol. 2001;69(1):77–84.CrossRefPubMed
44.
Abrantes AM, Strong DR, Ramsey SE, Kazura AN, Brown RA. HIV-risk behaviors among psychiatrically hospitalized adolescents with and without comorbid SUD. J Dual Diagn. 2006;2(3):85–100.CrossRefPubMed
45.
Bauer LO. A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS. Brain Cogn. 2008;67(1):103–14.CrossRefPubMed
46.
Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology. 1999;21(4):474–84.CrossRefPubMed
47.
Perry W, Braff DL. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry. 1994;151(3):363–7.PubMed
48.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta: U.S. Department of Health and Human Services; 2006.
49.
Teplin LA, Elkington KS, McClelland GM, et al. Major mental disorders, substance use disorders, comorbidity, and HIV-AIDS risk behaviors in juvenile detainees. Psychiatr Serv. 2005;56(7):823–8.CrossRefPubMed
50.
Stacy AW, Newcomb MD, Ames SL. Implicit cognition and HIV risk behavior. J Behav Med. 2000;23(5):475.CrossRefPubMed
51.
Fromme K, D’Amico EJ, Katz EC. Intoxicated sexual risk taking: an expectancy or cognitive impairment explanation? J Stud Alcohol. 1999;60(1):54–63.PubMed
52.
Dolezal C, Meyer-Bahlburg HFL, Remien RH, Petkova E. Substance use during sex and sensation seeking as predictors of sexual risk behavior among HIV+ and HIV− gay men. AIDS Behav. 1997;1(1):19–28.CrossRef
53.
Gonzalez R, Vassileva J, Bechara A, et al. The influence of executive functions, sensation seeking, and HIV serostatus on the risky sexual practices of substance-dependent individuals. J Int Neuropsychol Soc. 2005;11(2):121–31.CrossRefPubMed
54.
Loxley W, Davidson R. How rational is needle sharing to young injecting drug users? Addict Res Theory. 1998;6(6):499–515.CrossRef
55.
Mitchell MM, Severtson SG, Latimer WW. Interaction of cognitive performance and knowing someone who has died from AIDS on HIV risk behaviors. AIDS Educ Prev. 2007;19(4):289–97.CrossRefPubMed
56.
De Castro S, Sabate E. Adherence to heroin dependence therapies and human immunodeficiency virus/acquired immunodeficiency syndrome infection rates among drug abusers. Clin Infect Dis. 2003;37(s5):S464–7.CrossRefPubMed
57.
Wong KH, Lee SS, Lim WL, Low HK. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003;24(3):233–9.CrossRefPubMed
58.
Avants SK, Margolin A, McKee S. A path analysis of cognitive, affective, and behavioral predictors of treatment response in a methadone maintenance program. J Subst Abuse. 2000;11(3):215–30.CrossRefPubMed
59.
Passetti F, Clark L, Mehta MA, Joyce E, King M. Neuropsychological predictors of clinical outcome in opiate addiction. Drug Alcohol Depend. 2008;94(1–3):82–91.CrossRefPubMed
60.
Paulus MP, Tapert SF, Schuckit MA. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Arch Gen Psychiatry. 2005;62(7):761–8.CrossRefPubMed
61.
Hirsch MS, Conway B, D’Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society—USA Panel. JAMA. 1998;279(24):1984–91.CrossRefPubMed
62.
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279(24):1977–83.CrossRefPubMed
63.
Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50.PubMed
64.
Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMed
65.
Woods SP, Dawson MS, Weber E, et al. Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009;15(1):42–52.CrossRefPubMed
66.
Contardo C, Black AC, Beauvais J, Dieckhaus K, Rosen MI. Relationship of prospective memory to neuropsychological function and antiretroviral adherence. Arch Clin Neuropsychol. 2009;24(6):547–54.CrossRefPubMed
67.
Waldrop-Valverde D, Jones DL, Weiss S, Kumar M, Metsch L. The effects of low literacy and cognitive impairment on medication adherence in HIV-positive injecting drug users. AIDS Care. 2008;20(10):1202–10.CrossRefPubMed
68.
Blume AW, Davis JM, Schmaling KB. Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. J Psychoactive Drugs. 1999;31(2):111–5.PubMed
69.
Morgenstern J, Bates ME. Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment. J Stud Alcohol. 1999;60(6):846–55.PubMed
70.
Blume AW, Marlatt GA. The role of executive cognitive functions in changing substance use: what we know and what we need to know. Ann Behav Med. 2009;37(2):117–25.CrossRefPubMed
71.
Altice FL, Sullivan LE, Smith-Rohrberg D, et al. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis. 2006;43(Suppl 4):S178–83.CrossRefPubMed
72.
Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend. 2004;74(2):205–9.CrossRefPubMed
73.
Kouri EM, Lukas SE, Mendelson JH. P300 assessment of opiate and cocaine users: effects of detoxification and buprenorphine treatment. Biol Psychiatry. 1996;40(7):617–28.CrossRefPubMed
74.
Pirastu R, Fais R, Messina M, et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend. 2006;83(2):163–8.CrossRefPubMed
75.
Bruce RD, Govindasamy S, Sylla L, et al. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse. 2008;34(4):511–7.CrossRefPubMed
76.
Greenwald M, Johanson C-E, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101–10.CrossRefPubMed
77.
Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology (Berl). 2003;170(3):225–34.CrossRef
78.
Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20(14):1885–8.CrossRefPubMed
79.
Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.CrossRefPubMed
80.
Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48(1):17–28.CrossRefPubMed
81.
Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25(2):233–56.PubMed
82.
Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36(1):562–6.CrossRefPubMed
83.
Springer S, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009;21(8):976–83.CrossRefPubMed
84.
Cysique LAJ, Maruff P, Brew BJ. Antiretroviral therapy in hiv infection: are neurologically active drugs important? Arch Neurol. 2004;61(11):1699–704.CrossRefPubMed
85.
Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS. 2002;16(14):1867–76.CrossRefPubMed
86.
Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73(5):342–8.CrossRefPubMed
87.
Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):168–73.CrossRefPubMed
88.
Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS. 1999;13(14):1889–97.CrossRefPubMed
89.
McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS. 2007;21(9):1109–17.CrossRefPubMed
90.
Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29(10):865–74.CrossRefPubMed
91.
Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34(3):483–93.CrossRefPubMed
92.
Wexler BE, Anderson M, Fulbright RK, Gore JC. Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. Am J Psychiatry. 2000;157(10):1694–7.CrossRefPubMed
93.
Fals-Stewart W, Schafer J, Lucente S, Rustine T, Brown L. Neurobehavioral consequences of prolonged alcohol and substance abuse: a review of findings and treatment implications. Clin Psychol Rev. 1994;14(8):755–78.CrossRef
94.
Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004;26(2):67–78.CrossRefPubMed
95.
Margolin A, Kelly Avants S, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003;22(2):223–8.CrossRefPubMed
96.
Fisher WA, Fisher JD, Pryor JB, Reeder GD. A general social psychological model for changing AIDS risk behavior. The social psychology of HIV infection. Hillsdale: Lawrence Erlbaum Associates; 1993. p. 127–53.
97.
Carey MP, Carey KB, Maisto SA, et al. Reducing HIV-risk behavior among adults receiving outpatient psychiatric treatment: results from a randomized controlled trial. J Consult Clin Psychol. 2004;72(2):252–68.CrossRefPubMed
98.
Morin SF, Shade SB, Steward WT, et al. A behavioral intervention reduces HIV transmission risk by promoting sustained serosorting practices among HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008;49(5):544–51.CrossRefPubMed
99.
Carrico AW, Chesney MA, Johnson MO, et al. Randomized controlled trial of a cognitive-behavioral intervention for HIV-positive persons: an investigation of treatment effects on psychosocial adjustment. AIDS Behav. 2009;13(3):555–63.CrossRefPubMed
100.
Kalichman SC. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. Psychosom Med. 2008;70(5):593–7.CrossRefPubMed
101.
Tross S, Campbell A, Cohen L, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of a NIDA clinical trials network trial. J Acquir Immune Defic Syndr. 2008;48(5):581.CrossRefPubMed
102.
Calsyn DA, Hatch-Maillette M, Tross S, et al. Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J Subst Abuse Treat. 2009;37(2):138–50.CrossRefPubMed
Metadaten
Titel
Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship
verfasst von
Pria Anand
Sandra A. Springer
Michael M. Copenhaver
Frederick L. Altice
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 6/2010
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-010-9684-1

Weitere Artikel der Ausgabe 6/2010

AIDS and Behavior 6/2010 Zur Ausgabe

Brief Report

Biomarker Testing to Estimate Under-Reported Heavy Alcohol Consumption by Persons with HIV Initiating ART in Uganda

Original Paper

Bloody Traditional Procedures Performed During Infancy in the Oropharyngeal Area Among HIV+ Children: Implication from the Perspective of Mother-to-Child Transmission of HIV

Original Paper

Using Mobile Phones to Improve Clinic Attendance Amongst an Antiretroviral Treatment Cohort in Rural Uganda: A Cross-sectional and Prospective Study

Brief Report

Internet Use and the Network Composition of People Living with HIV/AIDS in an Urban Area in Peru

Original Paper

Reconsidering the Internet as an HIV/STD Risk for Men Who Have Sex with Men

Original Paper

Physiological and Psychosocial Factors that Predict HIV-Related Fatigue

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise